We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GBK:KSEGulf Bank K.S.C. Analysis

Data as of 2026-03-16 - not real-time

€2.52

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Turkiye Garanti Bankasi A.S. trades at €2.52, well below its 20‑day (≈€2.77) and 50‑day (≈€2.80) simple moving averages, indicating a short‑term pricing weakness. The RSI of 42 and a bearish MACD reinforce a neutral‑to‑bearish technical outlook, while the price sits just above a clear support level around €2.40 and far below the resistance near €3.04. On the valuation side, the bank’s PE ratio of 4.9 is dramatically lower than the industry average of 16.3, suggesting it is undervalued. Fundamental strengths include a robust ROE of 28.6%, a healthy profit margin of 33%, and a solid dividend yield of 4.0% with a modest payout ratio of 17%, indicating dividend sustainability. Recent material news points to a regulatory investigation by the Competition Board, the sale of a non‑performing‑loan portfolio, and the redemption of medium‑term notes, which together add regulatory and credit‑quality considerations. High 30‑day volatility (>100%) and low beta (≈0.18) imply the stock moves sharply but is relatively insulated from broader market swings. Liquidity appears thin, with daily volumes under 2,000 shares, raising execution concerns. Overall, the stock presents a value‑oriented opportunity with attractive yields, but investors must weigh regulatory risk and liquidity constraints.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support
  • Bearish MACD and RSI below 50
  • Regulatory investigation adds uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued PE relative to peers
  • Strong ROE and dividend yield
  • NPL portfolio sale expected to improve asset quality

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained profitability and high ROE
  • Attractive dividend with low payout ratio
  • Long‑term undervaluation despite short‑term volatility

Key Metrics & Analysis

Financial Health

Revenue Growth36.60%
Profit Margin33.40%
P/E Ratio4.9
ROE28.60%
ROA2.95%
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI42.3
Support€2.40
Resistance€3.04
MA 20€2.77
MA 50€2.80
MA 200€2.71
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

GradeUndervalued
TypeBlend
Dividend Yield4.03%

Risk Assessment

Beta0.18
Volatility106.39%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.